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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Asthma is a chronic airway inflammatory disease mediated
by T-helper (Th)2 cells. Montelukast (trade name Singulair) is a cysteinyl leukotriene receptor
antagonist used for asthma treatment. Mirroring Th1eTh2 polarization, two distinct states of
macrophages have been recognized: the classically activated (M1) macrophages and the alter-
natively activated (M2) macrophages. M2 polarization is known to be a response to the Th2 cy-
tokines; however, the effects of montelukast on M2 macrophages have not been well
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Journal of Microbiology, Immunologyon the expression of cytokines and chemokines in M2-like macrophages, and to explore possible
intracellular signaling pathways.
Methods: The human monocytic leukemia cell line THP-1 and human monocytes from healthy
donors were cultured with interleukin-4 for M2 polarization, and then the cells were pretreated
with or without montelukast before lipopolysaccharide (LPS) stimulation. Supernatants were
collected to determine interleukin-10, I-309/CCL1, and MDC/CCL22 levels by enzyme-linked
immunosorbent assay. Intracellular signaling was investigated using nuclear factor (NF)-kB in-
hibitors, mitogen-activated protein kinase (MAPK) inhibitors, and western blot analysis.
Results: LPS-induced interleukin-10 and I-309/CCL1 expression was significantly suppressed by
montelukast in THP-1-derived and human monocyte-derived M2 macrophages after LPS stimu-
lation. MDC/CCL22 expression was only significantly suppressed by montelukast in THP-1-
derived M2 macrophages after 48 hours of incubation. In western blot analysis, montelukast
was able to suppress LPS-induced MAPK-phospho-p38 and NF-kB-phospho-p65 expression.
Conclusion: Montelukast suppressed LPS-induced M2-related cytokines and chemokines in
alternatively activated macrophages, and the effects might be mediated through the MAPK-
p38 and NF-kB-p65 pathways.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Asthma is a chronic inflammatory disorder of the airways
characterized by bronchial hyper-responsiveness with var-
iable symptoms of recurring wheezing, coughing, and
shortness of breath. Recently, the prevalence of asthma
has grown in children, and it is associated with a large
percentage of allergy-related comorbidity.1e3 It is known
that T-helper 2 (Th2) cells promote eosinophilic inflamma-
tion and mediate the pathogenesis of asthma.4,5
Macrophages are major airway immunocytes that are
involved in lung immune homeostasis through phagocytosis
and chemokine secretion in response to antigens. Regula-
tion of phenotypes of pulmonary macrophages contributes
to the pathogenesis of asthma.6 Mirroring Th1eTh2 polari-
zation, two distinct states of macrophages have been
recognized: the classically activated (M1) macrophage
phenotype and the alternatively activated (M2) macro-
phage phenotype.7 While macrophages would typically be
expected to polarize toward the M1 phenotype by Th1
cytokine interferon-g, M2 polarization was originally
discovered as a response to the Th2 cytokine interleukin
(IL)-4.8 M1 and M2 macrophages have distinct chemokine
profiles. M1 macrophages express Th1 cell-attracting che-
mokines such as chemokine ligands CXCL9 and CXCL10.9 M2
macrophages could be derived from resting macrophages by
exposure to IL-4 or -13, and is characterized by expression
of arginase-1, Ym-1, Fizz-1, mannose receptors, and scav-
enger receptors.10 Chemokine ligands CCL1 (also known as
I-309), CCL16, CCL17, CCL18, CCL22 (also known as MDC),
and CCL24, and chemokine receptors CCR2, CXCR1, and
CXCR2 are classified to characterize the M2 state.11
The regulatory roles of M2 macrophages in asthma
remain controversial. Originally, M2 macrophages were re-
ported to be negative regulators of immune response
modulation, tissue repair, and restoration of homeostasis in
the lung microenvironment.12,13 However, recent studies
found increased alternative activation of macrophages inin Y-C, et al., Effects of montelu
and Infection (2016), http://dx.the lungs of asthmatic patients relative to healthy control
individuals, and excessive M2 macrophages may increase
cell recruitment and mucus secretion, resulting in airway
hyper-responsiveness.14,15 Roles of M2 macrophages in
asthma have not been well characterized.
Montelukast, trade name Singulair (Merck & Co., Inc.,
Kenilworth, NJ, USA), is a cysteinyl leukotriene receptor
(cysLTR) antagonist that is used for the treatment of
asthma.16 In the airways and lungs, leukotriene is released by
neutrophils, eosinophils, macrophages, epithelial cells, and
vascular endothelial cells, and is involved in smooth muscle
contraction, blood vessel dilatation, mucus secretion, and
eosinophil recruitment.17 It has been shown that the cysLTR
plays a more important role than cysteinyl leukotriene in the
pathogenesis of allergic airway inflammation.18 Previous
studies have demonstrated that montelukast significantly
improves airway inflammation, pulmonary function, and
symptom score in asthmaticwheezing infants comparedwith
those in a placebo group19 and reduces asthma exacerba-
tions in children with asthma.20,21
Studies of the effects of leukotriene receptor antagonist
on M2 macrophages are limited. Endotoxin, a lipopolysac-
charide (LPS) from the outer membrane of Gram-negative
bacteria, has been known to be a potent activator of
macrophages and may induce exacerbation of asthma.7 In
the present study, we investigated the effects of mon-
telukast on M2-related cytokine and chemokine activity in
LPS-stimulated THP-1-derived and human monocyte-
derived M2 macrophages and the possible intracellular
mechanisms.Methods
Cell preparation and reagents
The human monocytic cell line THP-1 (American Type Cul-
ture Collection, Rockville, MD, USA) was cultured in RPMIkast on M2-related cytokine and chemokine in M2 macrophages,
doi.org/10.1016/j.jmii.2016.04.005
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supplemented with 10% fetal bovine serum, 100 U/mL of
penicillin, and 100 mg/mL of streptomycin at 37C and 5%
CO2 in a humidified incubator. Cells were centrifuged (1500
rpm, 5 min) and resuspended in fresh media in 24-well
plates at a concentration of 5  105/mL for 24 hours
before experimental use. THP-1 cells were cultured with
phorbol 12-myristate 13-acetate (20 ng/mL) and IL-4
(20 ng/mL) for 3 days for M2 macrophage polarization, as
described in a published study.22 Mononuclear cells from
peripheral blood samples collected from healthy donors
were isolated by density-gradient centrifugation (Lympho-
prep; Axis-Shield PoC AS, Oslo, Norway), and the primary
monocytes were isolated by magnetic bead sorting with
anti-CD14 monoclonal antibody (MACS; Miltenyi Biotec,
Bergisch Gladbach, Germany). The study protocol was
approved by the Institutional Review Board of Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan and
informed consent was obtained, according to the Declara-
tion of Helsinki. The purity of the CD14þ monocytes was >
95%, and the CD14þ monocytes were cultured with IL-4
(20 ng/mL) for 3 days for M2 macrophage polarization, as
described in previous studies.23,24
THP-1-derived and human monocyte-derived M2 macro-
phages were pretreated with and without montelukast
(107e105M; Sigma Chemical Co.) for 2 hours before LPS
(0.2 mg/mL; Escherichia coli; Sigma Chemical Co.) stimu-
lation. The mitogen-activated protein kinase (MAPK)-p38
inhibitor (SB203580), MAPK-c-Jun N-terminal kinase (JNK)
inhibitor (SP600125), MAPK-extracellular signal-regulated
kinase (ERK) inhibitor (PD98059), and nuclear factor (NF)-
kB-p65 inhibitor (BAY117085) were used in the signal
pathway analysis. All MAPK and NF-kB inhibitors were ob-
tained from Sigma Chemical Company. The cell supernatant
was collected after 24 hours and 48 hours of incubation.
Enzyme-linked immunosorbent assay
Concentrations of IL-10, MDC/CCL22, and I-309/CCL1 were
measured by enzyme-linked immunosorbent assay kits
following the manufacturer’s protocol (R&D Systems Inc.,
Minneapolis, MN, USA). Samples were measured in a Dyna-
tech MRX plate reader at 450 nm and 540 nm using Reve-
lation software (Dynatech Laboratories Ltd., Alexandria,
VA, USA).
Cell viability
Montelukast was dissolved in dimethyl sulfoxide and diluted
to the final concentrations with phosphate-buffered saline.
Various concentrations of montelukast were incubated in
96-well plates for 24 hours. WST-1 activation solution was
mixed and diluted at a ratio of 1:50. Then, 50 mL of the
reaction solution was added to each well, and the plate was
incubated for 5 hours. Cell viability was calculated by
measuring the absorbance of the sample with an enzyme-
linked immunosorbent assay reader (Bio-Rad Benchmark
Plus microplate spectrophotometer, Bio-Rad Laboratories,
Hercules, CA, USA) at a wavelength of 470 nm and the
reference wavelength of 650 nm. The mean value was used
to assess the cell viability expressed as percent of control.Please cite this article in press as: Lin Y-C, et al., Effects of montelu
Journal of Microbiology, Immunology and Infection (2016), http://dx.Western blotting analysis
After treatment for 2 hours with or without montelukast
(106e105M), the cells were stimulated with LPS (0.2 mg/
mL) for 30 minutes and lysed with equal volume of ice-cold
150 mL lysis buffer [20mM Tris-HCl (pH 7.5), 150mM NaCl,
1mM Na2EDTA, 1mM Ethylene glycol tetraacetic acid
(EGTA), 1% Triton, 2.5mM sodium pyrophosphate, 1mM
beta-glycerophosphate, 1mM Na3VO4, 1 mg/mL leupeptin,
and protease inhibitor mixture]. After centrifugation at
13,000g for 15 minutes, equal amounts of cell lysates were
transferred to a nitrocellulose membrane and blocked with
Tris-buffered saline containing 1% nonfat dry milk and 0.1%
Tris-buffered saline and Tween 20 for at least 2 hours. After
washing three times with Tris-buffered saline and Tween
20, the membranes were incubated with primary antibodies
(diluted 1:2000 in phosphate-buffered saline), including
anti-MAPK (p38, ERK, and JNK; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-phospho-MAPK (phospho-p38,
phospho-ERK, and phospho-JNK; Santa Cruz Biotechnology),
anti-NF-kB (p65), and anti-phosphor-NF-kB (phosphor-p65;
Cell Signaling Technology, Danvers, MA, USA), at 4C over-
night. The membranes were then incubated with secondary
antibodies (diluted 1:5000 in phosphate-buffered saline).
Immunoreactive bands were visualized using a chem-
iluminescence system (Amersham Pharmacia Biotech, Sun-
nyvale, CA, USA).
Statistical analyses
All data are presented as the mean  standard deviation.
All experiments were performed in at least triplicate, and
differences between experimental and control groups were
analyzed using a one-way analysis of variance test. A p
value < 0.05 indicated a statistically significant difference
between groups.Results
Effects of montelukast on IL-10, I-309/CCL1, and
MDC/CCL22 expression in THP-1-derived and
human monocyte-derived M2 macrophages
To determine the effect of montelukast on cytokine and
chemokine expression in M2 macrophages, M2 macrophages
derived from THP-1 and human primary monocytes were
pretreated with various concentrations of montelukast
(107e105M) for 2 hours before LPS stimulation. The
montelukast concentrations that we used in the present
study are in the 107e105M concentration range, in
agreement with cysteinyl leukotriene type 1 receptor
antagonist activity that has been demonstrated in previous
studies.25,26 In THP-1-derived M2 macrophages, the results
showed that montelukast (106M and 105M) significantly
suppressed LPS-induced IL-10 after 24 hours of LPS stimu-
lation (Fig. 1A), and montelukast (105M) also significantly
suppressed LPS-induced IL-10 after 48 hours of LPS stimu-
lation (Fig. 1B). Montelukast (107e105M) significantly
suppressed I-309/CCL1 in a dose-dependent manner after
24 hours of LPS stimulation (Fig. 1C), and also significantlykast on M2-related cytokine and chemokine in M2 macrophages,
doi.org/10.1016/j.jmii.2016.04.005
Figure 1. Effects of montelukast on IL-10, I-309/CCL1, and MDC/CCL22 expression in THP-1-derived M2 macrophages. THP-1-
derived M2 macrophages were pretreated with various concentrations of montelukast (107e105M) for 2 hours before LPS
(0.2 mg/mL) stimulation. Montelukast significantly suppressed LPS-induced IL-10 expression in THP-1-derived M2 macrophages after
(A) 24 hours and (B) 48 hours of LPS stimulation. Montelukast significantly suppressed LPS-induced I-309/CCL1 expression in THP-1-
derived M2 macrophages after (C) 24 hours and (D) 48 hours of LPS stimulation. (E) Pretreatment of montelukast (107e105M) had
no effect on MDC/CCL22 expression after 24 hours of LPS stimulation. (F) MDC/CCL22 expression was significantly suppressed after
48 hours of LPS stimulation by montelukast. The bars represent the means  standard deviations from three replicated experi-
ments. * p < 0.05 compared with LPS alone. ** p < 0.01 compared with LPS alone. *** p < 0.001 compared with LPS alone.
IL Z interleukin; LPS Z lipopolysaccharide.
4 Y.-C. Lin et al.
+ MODELsuppressed I-309/CCL1 expression at concentrations of
106M and 105M after 48 hours of LPS stimulation (Fig. 1D).
Treatment with montelukast (107e105M) appeared to not
suppress MDC/CCL22 expression after 24 hours (Fig. 1E),
but to significantly suppress MDC/CCL22 expression after
48 hours of LPS stimulation (Fig. 1F) in THP-1-derived M2
macrophages. In human primary monocyte-derived M2
macrophages, montelukast (105M) significantly suppressed
IL-10 and I-309/CCL1 expression, but not MDC/CCL22
expression, after 24 hours of LPS stimulation (Fig. 2). We
found that LPS-induced IL-10 and I-309/CCL1 expression
was significantly suppressed by montelukast in both THP-1-
derived and human monocyte-derived M2 macrophages
after LPS stimulation. MDC/CCL22 expression was only
significantly suppressed by montelukast in THP-1-derived
M2 macrophages after 48 hours of incubation.
Montelukast had no cytotoxic effects on M2
macrophages
Owing to the observed suppressive effect of montelukast on
LPS-induced IL-10, I-309/CCL1, and MDC/CCL22 expression,
we next determined the cytotoxic effect of montelukast on
THP-1-derived and human monocyte-derived M2 macro-
phages at the concentrations employed in the experimentPlease cite this article in press as: Lin Y-C, et al., Effects of montelu
Journal of Microbiology, Immunology and Infection (2016), http://dx.(106M and 105M) by WST-1 assay. Montelukast had no sig-
nificant inhibition of cell viability compared with the control
group (dimethyl sulfoxide only) in THP-1-derived M2 mac-
rophages after 24 hours and 48 hours of incubation (Fig. 3A
and 3B). As shown in Fig. 3C, montelukast also had no cyto-
toxic effects on human monocyte-derived M2 macrophages.MAPK and NF-kB pathways may be involved in LPS-
induced IL-10, I-309/CCL1, and MDC/CCL22
production in THP-1-derived M2 macrophages
We used various inhibitors to explore the key signaling
pathway for M2-associated IL-10, I-309/CCL1, and MDC/
CCL22. Our data showed that IL-10 was inhibited by
SB203580 (p38 inhibitor), SP600125 (JNK inhibitor),
PD98059 (ERK inhibitor) (Fig. 4A), and BAY117085 (p65
inhibitor; Fig. 4B). I-309/CCL1 was suppressed by the JNK
inhibitor, ERK inhibitor (Fig. 4C), and p65 inhibitor
(Fig. 4D). We previously reported that SB203580 (p38 in-
hibitor) and SP600125 (JNK inhibitor) could suppress LPS-
induced MDC/CCL22 in THP-1 cells.27 These data sug-
gested that MAPK and NF-kB pathways were important
for LPS-induced IL-10, I-309/CCL1, and MDC/CCL22
synthesis.kast on M2-related cytokine and chemokine in M2 macrophages,
doi.org/10.1016/j.jmii.2016.04.005
Figure 2. Effects of montelukast on IL-10, I-309/CCL1, and MDC/CCL22 expression in human monocyte-derived M2 macrophages.
The human primary monocytes from healthy donors were cultured with IL-4 (20 ng/mL) for 3 days for M2 macrophage polarization
and then were pretreated with montelukast (107e105M) for 2 hours before LPS (0.2 mg/mL) stimulation. Montelukast (105M)
significantly suppressed (A) IL-10 and (B) I-308/CCL1, but not (C) MDC expression after 24 hours of LPS stimulation in human
monocyte-derived M2 macrophages. The bars represent the means  standard deviations from three replicated experiments. *
p < 0.05 compared with LPS alone. ** p < 0.01 compared with LPS alone. IL Z interleukin; LPS Z lipopolysaccharide.
Figure 3. Effects of montelukast on cell viability of M2 macrophages. THP-1-derived M2 macrophages were pretreated with
106M and 105M montelukast in a 96-well plate for (A) 24 hours and (B) 48 hours. (C) Human monocyte-derived M2 macrophages
were pretreated with 106M and 105M montelukast in a 96-well plate for 24 hours. Cell viability was determined by a WST-1 assay.
Bars represent the means  standard deviations of six individual experiments in THP-1-derived M2 macrophages and four individual
experiments in human monocyte-derived M2 macrophages.
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chemokine expression in THP-1-derived M2
macrophages via MAPK-p38 and NF-kB pathways
We investigated the effects of montelukast on the phos-
phorylation of the MAPK family and NF-kB by western blot.Please cite this article in press as: Lin Y-C, et al., Effects of montelu
Journal of Microbiology, Immunology and Infection (2016), http://dx.Fig. 4 shows that montelukast suppressed the expression of
LPS-induced phosphorylation of p38 (Fig. 5A), but not ERK
(Fig. 5B) or JNK (Fig. 5C). Phosphorylation of p65 was also
affected by montelukast, which indicated that NF-kB might
be the cardinal signaling target for the suppressive effect of
montelukast in THP-1-derived M2 macrophages (Fig. 5D).kast on M2-related cytokine and chemokine in M2 macrophages,
doi.org/10.1016/j.jmii.2016.04.005
Figure 4. MAPK and NF-kB inhibitors suppressed LPS-induced IL-10 and I-309/CCL1 expression in THP-1-derived M2 macrophages.
(A) MAPK inhibitors (1mM or 10mM), including SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and PD98059 (ERK inhibitor), and
(B) BAY117085 [an NF-kB (p65) inhibitor] significantly suppressed LPS-induced IL-10 expression. I-309/CCL1 was significantly sup-
pressed by (C) SP600125, PD98059, and (D) BAY117085. * p < 0.05 compared with LPS alone. ERK Z extracellular signal-regulated
kinase; ILZ interleukin; JNKZ c-Jun N-terminal kinase; LPSZ lipopolysaccharide; MAPKZmitogen-activated protein kinase; NF-
kB Z nuclear factor-kB.
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involve the MAPK-p38 and NF-kB pathways.Discussion
Montelukast is the most widely prescribed cysLTR antago-
nist for the treatment of allergic rhinitis and exercise- and
aspirin-induced asthma. Montelukast is used to mediate the
symptoms of these illnesses by blocking leukotriene re-
ceptors and preventing the activation of proinflammatory
mediators in the airways. Montelukast is also used as add-
on therapy in patients with asthma whose symptoms are
poorly controlled by inhaled corticosteroid
monotherapy.28,29
Macrophages have important roles in several chronic
diseases, including asthma. The inflammatory response in
asthma is characterized by the recruitment of Th2 lym-
phocytes, which produce several cytokines, including IL-4,
IL-13, and IL-33, influencing airway macrophages toward
alternative (M2) polarization.10 In our study, montelukast
was capable of suppressing IL-10 and I-309/CCL1 expression
in LPS-stimulated THP-1-derived and human monocyte-
derived M2 macrophages. This is the first study to investi-
gate the effects of the cysLTR antagonist on M2-associated
chemokine/cytokine activity in human M2-like macro-
phages. Wu et al30 demonstrated that montelukast might
exert its anti-inflammatory effect through suppression of
Th2 cytokines. Their study showed that montelukast
significantly reduced the concentrations of IL-4, -5, andPlease cite this article in press as: Lin Y-C, et al., Effects of montelu
Journal of Microbiology, Immunology and Infection (2016), http://dx.-13, and also reduced the number of eosinophils in bron-
choalveolar lavage samples. Stelmach et al31,32 reported
that increasing IL-10 levels were detected in the serum and
supernatants of peripheral blood mononuclear cells
(PBMCs) from asthmatic children under montelukast treat-
ment. However, in our study, we found that LPS-induced IL-
10 expression was significantly suppressed by montelukast
in the supernatants of THP-1-derived and human monocyte-
derived M2 macrophages from healthy donors. In humans, it
has been demonstrated that IL-10 could be produced by Th1
and Th2 lymphocytes, cytotoxic T cells, mast cells, mono-
cytes, B lymphocytes, keratinocytes, and eosinophils.33,34
Immune cells in vivo always work in cross talk with other
cells as a network. The different findings between our study
and previous studies of the montelukast effects on IL-10
production might because the samples in those studies
were from serum and supernatants of PBMCs, the levels
would be the amount of IL-10 from various immune cells.
Our study focused on the effects of montelukast in M2
macrophages. Melgert et al15,35 reported that M2 macro-
phages were increased in both bronchoalveolar lavage fluid
and airway tissue of asthmatic patients, and might aggra-
vate allergic inflammation. It supported that M2 macro-
phages play an important role in the pathophysiology of
asthma. Another possible reason for the different effects of
montelukast on IL-10 levels might be the different donor
sources. Stelmach et al32 have demonstrated different re-
sponses of IL-10 concentration to montelukast under
different allergic conditions. The enhanced effect of
montelukast on IL-10 concentrations was found inkast on M2-related cytokine and chemokine in M2 macrophages,
doi.org/10.1016/j.jmii.2016.04.005
Figure 5. Western blot analysis of MAPK and NF-kB pathways. (A) Montelukast (1mM and 10mM) significantly downregulated LPS-
induced phospho-p38 expression, but did not significantly downregulate LPS-induced expression of (B) phospho-ERK or (C) phospho-
JNK in THP-1-derived M2 macrophages. (D) Phospho-p65 expression in THP-1-derived M2 macrophages was suppressed by mon-
telukast at 10mM. The standard deviation of the optical density data refers to three independent experiments, and one experiment
representative of the three is shown. * p < 0.05 compared with LPS alone. ** p < 0.01 compared with LPS alone.
ERK Z extracellular signal-regulated kinase; IL Z interleukin; JNK Z c-Jun N-terminal kinase; LPS Z lipopolysaccharide;
MAPK Z mitogen-activated protein kinase; NF-kB Z nuclear factor-kB.
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culture but not in unstimulated PBMC culture, and mon-
telukast also had no effect on IL-10 concentrations in su-
pernatants of children without clinical manifestation of
asthma. Our study measured the LPS-induced IL-10 levels in
the supernatants of THP-1-derived and human monocyte-
derived M2 macrophages from healthy donors instead of
asthmatic patients. Heterogeneity of IL-10 responsiveness
to montelukast in M2 macrophages derived from healthy
donors and asthmatic patients should be considered.
Montelukast exerts anti-inflammatory action through
cysLTR-independent mechanisms, as well as via direct
blockade of cysLTR.36 MAPK signal pathways are important
for many processes in immune responses, but the role of
MAPK in macrophages is less characterized.37 In this study,
the p38, JNK, and ERK inhibitors reversed the LPS-induced
IL-10 expression in THP-1-derived M2 macrophages. West-
ern blot analysis further showed that LPS-stimulated
phospho-p38 was significantly depressed under mon-
telukast pretreatment in a dose-dependent manner, which
was complementary to the inhibitor assay. However, thePlease cite this article in press as: Lin Y-C, et al., Effects of montelu
Journal of Microbiology, Immunology and Infection (2016), http://dx.p38 inhibitor did not suppress the expression of I-309 in
THP-1-derived M2 macrophages in our results. This in-
dicates that the effects of montelukast on chemokine I-309
may differ from those of IL-10, which was regulated
directly by the MAPK-p38 pathway in THP-1-derived M2
macrophages.
It has been reported that montelukast can inhibit the
activity of the transcription factor NF-kB in monocytes/
macrophages, interfering with the generation of various
proinflammatory proteins such as IL-8.38,39 In our study, we
found that the NF-kB inhibitor suppressed LPS-induced IL-
10 and I-309 expression in THP-1-derived M2 macrophages,
and western blot analysis showed that LPS-stimulated
phospho-p65 expression was depressed with higher con-
centrations of montelukast during pretreatment. Our re-
sults demonstrated that montelukast suppresses M2-related
cytokines and chemokines, including IL-10 and I-309, maybe
by interfering with the NF-kB pathway.
In the present study, we provided the first evidence that
montelukast could significantly suppress LPS-induced M2-
related cytokines and chemokines, including IL-10, I-309/kast on M2-related cytokine and chemokine in M2 macrophages,
doi.org/10.1016/j.jmii.2016.04.005
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+ MODELCCL1, and partial MDC/CCL22, in human M2 macrophages.
We also demonstrated that the effects might be mediated
through the MAPK-p38 and NF-kB pathways.
In conclusion, montelukast may exert anti-inflammatory
effects not only by directly blocking leukotriene receptors,
but also by inhibiting cytokine and chemokine expression in
alternatively activated macrophages through the MAPK-p38
and NF-kB pathways.
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